Development of CARG-2020, a Synthetic Oncolytic & Immunomodulating Virus, for Treatment & Prevention of Solid Tumors

Time: 3:30 pm
day: Day One


  • Providing an overview of CARG-2020, a synthetic oncolytic and immunomodulating virus designed for the treatment and prevention of solid tumors
  • Discussing the advantages of developing synthetic viruses, including improved safety profiles, enhanced tumor targeting capabilities, and the ability to incorporate multiple therapeutic functionalities
  • Addressing the safety considerations of CARG-2020, including its replication selectivity for tumor cells, absence of viral pathogenicity, and potential mitigation of off-target effects